Detalhe da pesquisa
1.
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 29(14): 1795-1807, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37905526
2.
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
Mult Scler
; 24(6): 795-804, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485186
3.
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
Mult Scler
; 24(13): 1725-1736, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28914581
4.
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program.
Mult Scler J Exp Transl Clin
; 10(2): 20552173241238632, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38784791
5.
Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry.
Mult Scler J Exp Transl Clin
; 9(3): 20552173231194353, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37641619
6.
Functional treatments in multiple sclerosis.
Curr Opin Neurol
; 24(3): 250-4, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21455067
7.
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Ther Adv Neurol Disord
; 14: 1756286420987941, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33737954
8.
Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
Neurology
; 97(9): e881-e889, 2021 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34193590
9.
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
J Neurol
; 267(10): 2851-2864, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32451615
10.
Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management.
Nat Clin Pract Urol
; 6(2): 96-107, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19198623
11.
iPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury response.
Exp Neurol
; 288: 114-121, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27865736
12.
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Adv Ther
; 33(7): 1231-45, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27251051
13.
Current and emerging therapies in multiple sclerosis: a systematic review.
Ther Adv Neurol Disord
; 5(4): 205-20, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22783370